<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02438553</url>
  </required_header>
  <id_info>
    <org_study_id>NRLF-0086-14-MMC-CTIL</org_study_id>
    <nct_id>NCT02438553</nct_id>
  </id_info>
  <brief_title>Short-term Effectiveness of Transcutaneous Nerve Stimulation in Reducing Migraine Related Pain</brief_title>
  <official_title>A Prospective, Randomized, Single Blind, Parallel-group, Placebo Controlled Clinical Study to Evaluate the Short-term Effectiveness of Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation (OS-TNS) in Reducing Migraine Related Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurolief Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurolief Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the short-term effectiveness of combined occipital
      and supraorbital transcutaneous nerve stimulation in reducing migraine related pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain visual analogue scale (VAS)</measure>
    <time_frame>20-60 minutes of treatment.</time_frame>
    <description>The primary endpoint will be defined based on relative change (%) in pain VAS score from baseline to end of treatment without using pain relief medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>&quot;Responder&quot; rate at 20-60 minutes of treatment.</measure>
    <time_frame>20-60 minutes of treatment.</time_frame>
    <description>- Evaluated using pain VAS; a responder will be defined by a decrease of 50% or more in the pain VAS from baseline to end of treatment without using pain relief medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&quot;Responder&quot; rate at 15 minutes of treatment</measure>
    <time_frame>Baseline, 15 minutes of treatment</time_frame>
    <description>Responder&quot; rate at 15 minutes of treatment - Evaluated using pain VAS; a responder will be defined by a decrease of 50% or more in the pain VAS from baseline to end of treatment without using pain relief medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained &quot;Responder&quot; rate at 24 hours post treatment</measure>
    <time_frame>Baseline, 24 hours post treatment</time_frame>
    <description>Sustained &quot;responders&quot; rate at 24 hours: The percentage of study participants who will be defined as a &quot;responder&quot; at 2 hour and will not use pain relief medication or suffer from relapse (recurrence) within the subsequent 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&quot;Headache relief&quot; rate- at 2 hours</measure>
    <time_frame>Baseline, 2 hours</time_frame>
    <description>&quot;Headache relief&quot; rate- the percentage of subjects with a decrease in headache from severe or moderate to none or mild within 2 hours, before any pain relief medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained &quot;headache relief&quot; at 24 hours</measure>
    <time_frame>Baseline, 24 hours</time_frame>
    <description>The percentage of study participants who will be defined as having a &quot;headache relief&quot; at 2 hour and will not use pain relief medication or suffer from relapse (recurrence) within the subsequent 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain free at 2 hours</measure>
    <time_frame>Baseline, 2 hours</time_frame>
    <description>Percentage of subjects that are pain free at 2 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained pain freedom at 24 hours</measure>
    <time_frame>Baseline, 24 hours</time_frame>
    <description>The percentage of study participants who will be defined as &quot;pain free&quot; at 2 hour and will not use pain relief medication or suffer from relapse (recurrence) within the subsequent 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional disability change 2 hours from end of treatment</measure>
    <time_frame>Baseline, 2 Hours post treatment</time_frame>
    <description>Functional disability change 2 hours from end of treatment without using pain relief medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until use of pain relief medication.</measure>
    <time_frame>Baseline- 24 hours.</time_frame>
    <description>Time until use of pain relief medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of nausea, vomiting, photophobia, phonophobia.</measure>
    <time_frame>Baseline- 24 hours.</time_frame>
    <description>Presence of nausea, vomiting, photophobia, phonophobia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who completed the treatment.</measure>
    <time_frame>Baseline-20 minutes of treatment</time_frame>
    <description>Percentage of subjects who completed at least 20 minutes the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global impression of effect</measure>
    <time_frame>Baseline- 24 hours.</time_frame>
    <description>Global impression of effect- A simple Likert-type verbal scale: very poor, poor, no opinion, good, very good.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Headache, Migraine</condition>
  <arm_group>
    <arm_group_label>OSTNS Neurostimulator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined Occipital &amp; Supraorbital Transcutaneous Neurostimulator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo OSTNS Neurostimulator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Combined Occipital &amp; Supraorbital Transcutaneous Neurostimulator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OSTNS Neurostimulator</intervention_name>
    <description>Non-invasive transcutaneous neurostimulation.</description>
    <arm_group_label>OSTNS Neurostimulator</arm_group_label>
    <other_name>Transcutaneous Neurostimulator.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo OSTNS Neurostimulator</intervention_name>
    <description>Placebo non-invasive transcutaneous neurostimulation</description>
    <arm_group_label>Placebo OSTNS Neurostimulator</arm_group_label>
    <other_name>Transcutaneous Neurostimulator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with confirmed diagnosis of migraine headache without aura or with typical
             migraine with aura (ICHD-II code 1.2.1 or 1.1).

          -  Subjects with 1-6 migraine episodes per month in the last 2 months.

          -  The subject is capable of understanding the study and to sign an informed consent.

        Exclusion Criteria:

          -  Subjects who have concomitant epilepsy.

          -  History of neurosurgical interventions.

          -  Subjects with metal implants or shrapnel in their head, except for dental implants.

          -  Subjects with implanted cardiac pacemaker, neurostimulators, surgical clips (above the
             shoulder line) or any medical pumps.

          -  History of drug abuse or alcoholism.

          -  History of medications overuse headache.

          -  Participation in current clinical study or participated in a clinical study within 3
             months prior to this study.

          -  Skin lesion or inflammation at the region of the stimulating electrodes.

          -  Personality or somatoform disorder.

          -  Pregnancy or Lactation.

          -  Women of reproductive age not using efficient contraceptive method.

          -  History of cerebrovascular event.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel Hering, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of headache clinic, Department of Neurology, Meir General Hospital, Kfar Saba, Israel.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Meir General Hospital</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 Jan 30;68(5):343-9.</citation>
    <PMID>17261680</PMID>
  </reference>
  <reference>
    <citation>Ahmed HE, White PF, Craig WF, Hamza MA, Ghoname ES, Gajraj NM. Use of percutaneous electrical nerve stimulation (PENS) in the short-term management of headache. Headache. 2000 Apr;40(4):311-5.</citation>
    <PMID>10759936</PMID>
  </reference>
  <reference>
    <citation>Loder E. Triptan therapy in migraine. N Engl J Med. 2010 Jul 1;363(1):63-70. doi: 10.1056/NEJMct0910887. Review.</citation>
    <PMID>20592298</PMID>
  </reference>
  <reference>
    <citation>Hann S, Sharan A. Dual occipital and supraorbital nerve stimulation for chronic migraine: a single-center experience, review of literature, and surgical considerations. Neurosurg Focus. 2013 Sep;35(3):E9. doi: 10.3171/2013.6.FOCUS13233. Review.</citation>
    <PMID>23991822</PMID>
  </reference>
  <reference>
    <citation>Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ; ONSTIM Investigators. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia. 2011 Feb;31(3):271-85. doi: 10.1177/0333102410381142. Epub 2010 Sep 22.</citation>
    <PMID>20861241</PMID>
  </reference>
  <reference>
    <citation>Schoenen J, Vandersmissen B, Jeangette S, Herroelen L, Vandenheede M, Gérard P, Magis D. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology. 2013 Feb 19;80(8):697-704. doi: 10.1212/WNL.0b013e3182825055. Epub 2013 Feb 6.</citation>
    <PMID>23390177</PMID>
  </reference>
  <reference>
    <citation>Schwedt TJ. Occipital nerve stimulation for chronic migraine--interpreting the ONSTIM feasibility trial. Cephalalgia. 2011 Feb;31(3):262-3. doi: 10.1177/0333102410383591. Epub 2010 Sep 16.</citation>
    <PMID>20847083</PMID>
  </reference>
  <reference>
    <citation>Silberstein SD, Dodick DW, Saper J, Huh B, Slavin KV, Sharan A, Reed K, Narouze S, Mogilner A, Goldstein J, Trentman T, Vaisman J, Ordia J, Weber P, Deer T, Levy R, Diaz RL, Washburn SN, Mekhail N. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2012 Dec;32(16):1165-79. doi: 10.1177/0333102412462642. Epub 2012 Oct 3. Erratum in: Cephalalgia. 2014 Oct;34(11):944. Vaisma, Julien [corrected to Vaisman, Julien]. Cephalalgia. 2014 Oct;34(11):944.</citation>
    <PMID>23034698</PMID>
  </reference>
  <results_reference>
    <citation>Tfelt-Hansen P, Pascual J, Ramadan N, Dahlöf C, D'Amico D, Diener HC, Hansen JM, Lanteri-Minet M, Loder E, McCrory D, Plancade S, Schwedt T; International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia. 2012 Jan;32(1):6-38.</citation>
    <PMID>22384463</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2015</study_first_submitted>
  <study_first_submitted_qc>May 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <last_update_submitted>January 6, 2016</last_update_submitted>
  <last_update_submitted_qc>January 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

